BioLife Solutions Merger with Repligen Clears HSR Antitrust Review
BLFS sits 96% above its 52-week low of $17.86.
Summary
BioLife Solutions announced that the HSR antitrust waiting period for its acquisition by Repligen has expired, moving the $1.5 billion merger closer to its expected Q4 2026 close.
Key Events · M&A and Partnerships · BLFS
-
HSR Waiting Period Expired
The Hart-Scott-Rodino (HSR) antitrust waiting period for the merger with Repligen expired on September 3, 2026, satisfying a key closing condition.
-
Merger Progresses
This development advances the previously announced $1.5 billion cash-and-stock acquisition by Repligen, which offers $11.25 cash and 0.1442 shares of Repligen common stock per BioLife share.
-
Stockholder Vote Pending
The merger remains subject to BioLife stockholder approval, with a special meeting scheduled for October 5, 2026.
Analysis · BLFS · Industrial Applications And Services
This filing provides a crucial update on the pending acquisition of BioLife Solutions by Repligen. The expiration of the Hart-Scott-Rodino (HSR) antitrust waiting period on September 3, 2026, removes a significant regulatory hurdle, bringing the $1.5 billion cash-and-stock deal closer to completion. The merger remains subject to BioLife stockholder approval, with a vote scheduled for October 5, 2026.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLFS was trading at $34.93 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $17.86 to $38.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.